Your session is about to expire
← Back to Search
Triple Drug Therapy for Leukemia
Study Summary
This trial is studying a combination of 3 drugs to treat leukemia. Decitabine and venetoclax work in different ways to stop the growth of cancer cells, and ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 171 Patients • NCT01935336Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have serious heart rhythm problems as decided by my doctor.I haven't taken experimental leukemia drugs in the last week, or I've recovered from their side effects.I do not have any serious or uncontrolled heart conditions.My heart's electrical activity is normal or corrected with treatment.I have another cancer that is expected to affect my survival within a year.I have or might have long QT syndrome.I have had a blood clot in my veins or lungs in the last 3 months, not including clots related to an IV line in my arm.I have a specific type of leukemia (Ph+ AML, AP-CML, or BP-CML).I can take care of myself but can't do heavy physical work.I am not pregnant or breastfeeding and, if capable of becoming pregnant, will use birth control during the study.I do not have an uncontrolled serious infection.I have had acute pancreatitis in the last 6 months or suffer from chronic pancreatitis.I haven't had a heart attack, stroke, or similar heart issues in the last 6 months.I can swallow.I have not eaten grapefruit, Seville oranges, or star fruit in the last 3 days.I do not have severe heart failure.
- Group 1: Treatment (ponatinib, venetoclax, decitabine)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has there been any further research done with Ponatinib outside of this trial?
"As of today, Ponatinib has been subject to 328 clinical studies with 45 of those trials currently in the third phase. Of these investigations, Toronto is the primary location however there are more than 9000 other sites participating research for this medication."
Are there any open opportunities to join this investigation?
"According to the details provided on clinicaltrials.gov, this medical investigation is actively soliciting participants for enrollment. The research was initially posted in May 2020 and recently modified in October 2022."
What is the general purpose of Ponatinib administration?
"Ponatinib is generally prescribed to patients with intermediate-2 IPSS risk scores. Furthermore, it has been effectively used in the treatment of refractory anemias, blast phase chronic myelocytic leukemia, and muscular dystrophy."
How many participants are involved in this trial?
"Affirmative. According to information found on clinicaltrials.gov, this research project is actively enrolling patients and was initially publicized on May 17th 2020 with an edit made as recently as October 31st 2022. The investigators are looking for 30 individuals from a single site to participate in the study."
To what extent does Ponatinib potentially pose a risk to individuals?
"Due to the limited clinical evidence in favor of Ponatinib's efficacy, our team at Power gave this medication a score of 2 on its safety rating scale."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger